|Bid||119.25 x 1100|
|Ask||119.29 x 900|
|Day's Range||117.54 - 119.46|
|52 Week Range||101.36 - 132.13|
|Beta (3Y Monthly)||0.16|
|PE Ratio (TTM)||14.45|
|Earnings Date||Jan 30, 2020|
|Forward Dividend & Yield||2.58 (2.19%)|
|1y Target Est||124.08|
Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D;, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. The new organization, named Loxo Oncology at Lilly, will be led jointly by Josh Bilenker, M.D., Jacob Van Naarden, and Nisha Nanda, Ph.D., and will report into Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. Lilly today also announced that David Hyman, M.D. will join the leadership team as chief medical officer of the new organization, beginning in January 2020. Dr. Hyman currently serves as chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center.
U.S. drugmaker Eli Lilly and Co said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired earlier this year. The move highlights Lilly's efforts to double down on its cancer business following the $8 billion acquisition of Loxo in February. The company has been focused on increasing sales in core franchises, including diabetes and oncology, as sales of older blockbuster medicines such as diabetes treatment Humalog and erectile dysfunction drug Cialis face pressure from generic competition.
Eli Lilly's new space in South San Francisco could provide a home for 10-15 small-but-growing life sciences companies.
Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:30 a.m., Eastern Time.
Pharmaceutical stocks rose a single-digit percentage in the first 11 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.
Eli Lilly and Company (NYSE: LLY) today unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise.
Eli Lilly and Company's (NYSE: LLY) first digital health open innovation challenge, "Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease," has concluded, with HealthVoyager, an application developed by Boston Children's Hospital and Klick Health, being named the winner. The idea leverages a highly customizable software platform for doctors to create a personalized and immersive educational experience for patients living with inflammatory bowel disease (IBD). At Lilly's headquarters in Indianapolis, five finalists presented their digital health solutions aimed at transforming IBD care, during which an expert panel of judges evaluated each idea's impact, novelty, technical feasibility and ability to address long-term needs of people with IBD.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]
Investing.com – President Donald Trump tweeted on Friday the federal government is working on a plan to let Florida and other states import lower-priced prescription drugs for residents.
Eli Lilly & Co. said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus. The drug maker said its plans are a result of increased demand for its medicines and for the production of additional capacity for future medicines, and are helped by having more capital available as a result of tax reform. "These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," said Myles O'Neill, president of manufacturing operations. "All of these projects support Lilly's investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics." The stock, which was still inactive in premarket trading, has slipped 0.5% year to date, while the SPDR Health Care Select Sector ETF has climbed 13.0% and the S&P 500 has advanced 24.5%.
INDIANAPOLIS, Nov. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans are driven by increasing demand for Lilly's current medicines, and they provide additional manufacturing capacity for future medicines coming from Lilly's pipeline. Company leaders were joined by state and local government officials at Lilly's headquarters in Indianapolis to unveil the details of the investments, which include enhancements to existing manufacturing facilities that make insulin, additional capacity for its growing portfolio of diabetes medicines and initial capital investments for future medicines.
INDIANAPOLIS, Nov. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance. The conference call will begin at 9 a.m. Eastern time.
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 17, 2019 /PRNewswire/ -- A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists. The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease.
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes. Empagliflozin 2.5 mg is an SGLT2 inhibitor being developed by Boehringer Ingelheim and Eli Lilly and Company (LLY). A separate brand name has been proposed for empagliflozin 2.5 mg in type 1 diabetes.